/Investor DB

Verve Ventures — 2024 Investments

9 investments dated 2024 · listed companies and verified rows first · show all

Bcompbcomp.comin𝕏Apr 2024 · $40M

Bcomp manufactures powerRibs™, a natural fibre reinforcement grid for composite structures that mimics leaf-vein patterns to provide high stiffness at minimal weight.

Advanced ManufacturingCircular EconomyCleantechNew MaterialsFribourg, CH

Christian Fischer(Founder)in

Co-investorsBMW i VenturesVenture KickAirbus VenturesGenerali VenturesPorsche VenturesRKKVC+1 more

Cubbitcubbit.ioin𝕏Jul 2024

Cubbit provides distributed cloud storage infrastructure that combines on-premises and cloud technologies to give companies data sovereignty and cost control.

Cloud ComputingCybersecurityData & InfrastructureDeep TechIoTBologna, IT

Alessandro Cillario(Founder)inLorenzo Posani(Founder)Marco Moschettini(Founder)Stefano Onofri(Founder)

Co-investorsCDP Venture CapitalETF PartnersGrowth CapitalGrowth EngineItalian Angels for GrowthLocalGlobe+6 more

Groovergroover.coin𝕏Feb 2024

Groover is a platform that connects independent music artists with curators, playlist programmers, radio stations, and record labels for promotion and feedback.

B2B MarketplacesCreator EconomyMarketing TechVauville, FR

Romain Palmieri(Founder)inDorian Perron(Founder)in

Co-investorsKima VenturesOneRagtimePartech VenturesTechstarsTrind VenturesBpifrance

Limulalimula.chMay 2024 · $6.8M

Limula develops an automated, closed platform for manufacturing personalized cell and gene therapies, aiming to move production from open, manual methods to scalable automated processes.

BiotechDeep TechHardwareMedical DevicesLausanne, CH

Thomas Eaton(Founder & CEO)inYann Pierson(Founder & CTO)inCaroline Boudousquié(Head of Solutions)inOlivier Waridel(Head of Operations)in

Co-investorsLifeX VenturesZühlke VenturesOxford Seed Fund

Memo Therapeutics AGmemo-therapeutics.cominMay 2024acquired by Clementia

Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.

BiotechMedical DevicesZurich, CH

Co-investorsKurma PartnersPureos BioventuresYsios CapitalAdjuvant CapitalFresenius Medical Care Venturesredalpine

Neustarkneustark.cominJun 2024 · $69M

Neustart develops CO2 mineralization technology that accelerates natural carbonation processes to sequester carbon dioxide in solid carbonate materials within minutes, which can be integrated into existing industrial infrastructure and used in construction applications.

Circular EconomyCleantechClimate TechNew Materials

Johannes Tiefenthaler(Founder)in

Co-investorsKickstart InnovationACE & CompanyBlume Equitybp venturesUBS

Somagenetixsomagenetix.cominOct 2024

Somagenetix is a gene therapy company that develops treatments for genetic diseases, particularly phagocyte-driven immune and neurodegenerative disorders, by correcting DNA at its source.

BiotechDeep TechHealthtechMedical DevicesZurich, CH

Co-investorsVI Partners

Tozerotozero.solutionsinNov 2024

ToZero Solutions develops a proprietary process to recover critical raw materials like lithium and graphite from end-of-life lithium-ion batteries for reintroduction into the supply chain.

Circular EconomyCleantechEnergy

Co-investorsAtlanticGlobal BrainHonda Innovations Silicon ValleyIn-Q-TelNordicNinjaPossible Ventures+2 more

Transmutextransmutex.cominJan 2024

Transmutex develops accelerator-powered technology that converts nuclear waste into clean energy and produces medical radioisotopes.

Deep TechEnergyMedical DevicesVernier (Geneva), CH

Franklin Servan-Schreiber(Founder & CEO)in

Co-investors4see VenturesAlleyCorpAt One VenturesHCVCHouse Of VenturesSteel Atlas+4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.